Abstract
Objective: The placebo effect is established in psychiatry, yet its role in substance use disorders (SUDs) treatment remains unclear. The aim of this study was to evaluate changes in craving scores in placebo groups in randomized controlled trials (RCTs) across different SUDs in adults.
Data sources: Eight different databases (PubMed, Embase, Web of Science, Cochrane Library, Emcare, MEDLINE, PsycINFO, and Academic Search) were systematically searched up to October 28, 2024, by 2 independent researchers.
Study selection: Placebo-controlled, double-blind RCTs assessing craving in patients with SUDs were included based on predefined eligibility criteria, published in English, Dutch, Spanish, or German language. Search terms were a combination and synonyms of “craving,” “addiction,” and “placebo.” From a total of 1945 unique records identified, 9 articles met our eligibility criteria.
Data extraction: Data on demographic characteristics, study design, and outcome results were extracted. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated for pre-post craving scores within each placebo group; a positive difference point towards improvement in the postplacebo period.
Results: A total of n=495 placebo-treated participants were included from nine RCTs in three different SUDs (n=300 in alcohol, n=88 in cocaine, and n=107 in methamphetamine use disorder). Craving scores significantly decreased over time (meaning symptom improvement) in the placebo treatment group in alcohol use disorder (5 studies, SMD=0.93 [95% CI=0.33 to 1.54]) but did not reach statistical significance in cocaine use disorder (2 studies, SMD=0.61 [95% CI=−1.41 to 2.62]) or in (meth)amphetamine use disorder (2 studies, SMD=0.44 [95% CI=−3.43 to 4.32]).
Conclusions: Placebo treatment led to reductions in craving scores across all three SUDs, although statistical significance was achieved only in alcohol use disorder. Given the low number of studies for cocaine and (meth)amphetamine use disorder, these estimates were captured with much uncertainty. These findings may inform the design of future RCTs and support the development of more individualized treatment approaches in clinical settings.
J Clin Psychiatry 2026;87(2):25r16118
Author affiliations are listed at the end of this article.
Members Only Content
This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.
References (21)
- Weimer K, Colloca L, Enck P. Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry. 2015;2(3):246–257. PubMed CrossRef
- Huneke NTM, van der Wee N, Garner M, et al. Why we need more research into the placebo response in psychiatry. Psychol Med. 2020;50(14):2317–2323. PubMed CrossRef
- Tavel ME. The placebo effect: the good, the bad, and the ugly. Am J Med. 2014;127(6):484–488. PubMed CrossRef
- Wolters F, Peerdeman KJ, Evers AWM. Placebo and nocebo effects across symptoms: from pain to fatigue, dyspnea, nausea, and itch. Front Psychiatr. 2019;10:470. PubMed CrossRef
- Bschor T, Nagel L, Unger J, et al. Differential outcomes of placebo treatment across 9 psychiatric disorders: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81(8):757–768. PubMed CrossRef
- Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–238. PubMed CrossRef
- Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci. 2012;1248(1):1–17. PubMed CrossRef
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. PubMed CrossRef
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898. PubMed CrossRef
- Team RCR. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2024.
- Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160. PubMed CrossRef
- de Bejczy A, Nations KR, Szegedi A, et al. Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2014;38(9):2427–2435. PubMed CrossRef
- Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677–1685. PubMed CrossRef
- Petrakis IL, Ralevski E, Gueorguieva R, et al. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction. 2018;113(1):6–14. PubMed CrossRef
- Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101(10):1451–1462. PubMed CrossRef
- Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691–1700. PubMed CrossRef
- Mongeau-Pérusse V, Brissette S, Bruneau J, et al. Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. Addiction. 2021;116(9):2431–2442. PubMed CrossRef
- Nanni-Alvarado R, Gonzalez M, Lima C, et al. Effect of mirtazapine on craving in cocaine-dependent patients. Int J Ment Health Addiction. 2022;20(5):2770–2786. CrossRef
- Javdan NS, Ghaderi A, Banafshe HR. The effects of quetiapine on craving and withdrawal symptoms in methamphetamine abuse: a randomized, double-blind, placebo-controlled trial. Int J Med Toxicol Forensic Med. 2020;10(4):29374.
- McKetin R, Dean OM, Turner A, et al. N-acetylcysteine (NAC) for methamphetamine dependence: a randomised controlled trial. EClinicalMedicine. 2021;38:101005. PubMed CrossRef
- Huneke NTM, Amin J, Baldwin DS, et al. Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: an umbrella review. Mol Psychiatr. 2024;29(12):3915–3925. PubMed CrossRef
